Clinical trialNCT06150664RecruitingPhase 1Interventional

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

SponsorCompass TherapeuticsEnrollment85Head and Neck Squamous Cell CarcinomaHodgkin LymphomaMalignant MelanomaNon Small Cell Lung CancerTriple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

D&h Cancer Research Center
Margate, Florida, United States
Withdrawn
Florida Cancer Specialists - Lake Nona
Orlando, Florida, United States
Cesar Perez Batista, MD
Recruiting
Florida Cancer Specialists - Sarasota
Sarasota, Florida, United States
Judy Wang, MD
Recruiting
University Cancer & Blood Center
Athens, Georgia, United States
Frederick Flynt, MD, FACP
Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Sunil Babu, MD
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Hollis Viray, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Patrick Ott, MD, PhD
Recruiting
Roswell Park Cancer Institute
Buffalo, New York, United States
Benjamin Switzer, DO
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Jeff Russell, MD
Recruiting
Summit Cancer Center
Spokane, Washington, United States
Arvind Chaudhry, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CTX-8371

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Mar 2024
Primary completion: 31 Dec 2026
Completion: 31 May 2027
Last update posted: 28 Jul 2026
Registered enrollment: 85
Registry id: NCT06150664

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.